Reply
- PMID: 34927750
- DOI: 10.1002/hep.32292
Reply
Comment on
-
Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.Hepatology. 2021 Nov;74(5):2452-2466. doi: 10.1002/hep.31995. Epub 2021 Aug 21. Hepatology. 2021. PMID: 34105780 Free PMC article.
-
Letter to the editor: Serum thrombospondin-2 as biomarker in liver diseases, a look beyond NASH.Hepatology. 2022 Apr;75(4):1056-1057. doi: 10.1002/hep.32291. Epub 2022 Jan 6. Hepatology. 2022. PMID: 34927752 No abstract available.
References
-
- Carpino G, Cardinale V, Di Giamberardino A, Overi D, Donsante S, Colasanti T, et al. Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma. J Hepatol. 2021;75(6):1377–86.
-
- Kozumi K, Kodama T, Murai H, Sakane S, Govaere O, Cockell S, et al. Transcriptomics identify thrombospondin‐2 as a biomarker for NASH and advanced liver fibrosis. Hepatology. 2021;74(5):2452–66.
-
- Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–88.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical